<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="20/11/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9384661" creator="Yo Shidahara">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>9384661</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Expression of <term sem="DNA_molecule" id="T1" lex="c-fos">c-fos</term> correlates with <term sem="Other" id="T2" lex="IFN-alpha_responsiveness"><term sem="Protein_molecule" id="T3" lex="IFN-alpha">IFN-alpha</term> responsiveness</term> in <term sem="Other" id="T4" lex="Philadelphia_chromosome_positive_chronic_myelogenous_leukemia"><term sem="DNA_molecule" id="A1">Philadelphia chromosome</term> positive chronic myelogenous leukemia</term>.</sentence>
<event id="E1">
<type class="Gene_expression" />
<theme idref="T1" />
<clue><clueType>Expression</clueType> <linkTheme>of</linkTheme> c-fos correlates with IFN-alpha responsiveness in Philadelphia chromosome positive chronic myelogenous leukemia.</clue>
</event>
<event id="E2">
<type class="Regulation" />
<cause idref="T3" />
<clue>Expression of c-fos correlates with IFN-alpha <clueType>responsiveness</clueType> in Philadelphia chromosome positive chronic myelogenous leukemia.</clue>
</event>
<event id="E3">
<type class="Correlation" />
<theme idref="E1" />
<theme idref="E2" />
<clue>Expression of c-fos <clueType>correlates</clueType> <linkTheme>with</linkTheme> IFN-alpha responsiveness <clueLoc>in Philadelphia chromosome positive chronic myelogenous leukemia</clueLoc>.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">This study evaluates (i) constitutive levels of <term sem="RNA_molecule" id="T5" lex="oncogene">oncogene</term> and <term sem="RNA_family_or_group" id="T6" lex="p53_transcript">p53</term> <term sem="RNA_molecule" id="A2">transcripts</term> in <term sem="Multicellular_organism_natural" id="T7" lex="chronic_phase_CML_patient">chronic phase CML patients</term> and (ii) their modulations subsequent to in vivo therapy with <term sem="Protein_molecule" id="T8" lex="rIFN-alpha_2c">rIFN-alpha 2c</term>.</sentence>
<event uncertainty="doubtful" id="E4">
<type class="Transcription" />
<theme idref1="A2" idref="T5" />
<clue>This study evaluates (i) constitutive <clueType>levels</clueType> <linkTheme>of</linkTheme> oncogene and p53 transcripts <clueLoc>in chronic phase CML patients</clueLoc> and (ii) their modulations subsequent to in vivo therapy with rIFN-alpha 2c.</clue>
<comment>NER T5,T6 MOD</comment>
</event>
<event uncertainty="doubtful" id="E5">
<type class="Transcription" />
<theme idref1="A2" idref="T6" />
<clue>This study evaluates (i) constitutive <clueType>levels</clueType> <linkTheme>of</linkTheme> oncogene and p53 transcripts <clueLoc>in chronic phase CML patients</clueLoc> and (ii) their modulations subsequent to in vivo therapy with rIFN-alpha 2c.</clue>
</event>
<sentence id="S3"><term sem="Cell_natural" id="T9" lex="peripheral_blood_mononuclear_cell">Peripheral blood mononuclear cells</term> (<term sem="Cell_natural" id="T10" lex="pbmc">pbmc</term>) and <term sem="Cell_natural" id="T11" lex="bone_marrow_cell">bone marrow cells</term> of 26 patients were examined for <cons sem="(AND Other Other Other Other)" id="T12" lex="(AND c-fos_mRNA_level c-myc_mRNA_level p53_mRNA_level the_hybrid_bcr/abl_mRNA_level)"><frag id="F1">c-fos</frag>, <frag id="F2">c-myc</frag>, <frag id="F3">p53</frag> and the <frag id="F4">hybrid bcr/abl</frag> <frag id="F5">mRNA</frag> <frag id="F6">levels</frag></cons>.</sentence>
<event uncertainty="doubtful" id="E6">
<type class="Transcription" />
<theme idref1="F5" idref="F1" />
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E106">
<type class="Transcription" />
<theme idref1="F5" idref="F1" />
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E7">
<type class="Transcription" />
<theme idref1="F5" idref="F2" />
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E107">
<type class="Transcription" />
<theme idref1="F5" idref="F2" />
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E8">
<type class="Transcription" />
<theme idref1="F5" idref="F3" />
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E108">
<type class="Transcription" />
<theme idref1="F5" idref="F3" />
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E9">
<type class="Transcription" />
<theme idref1="F5" idref="F4" />
<clue><clueLoc>Peripheral blood mononuclear cells (pbmc)</clueLoc> and bone marrow cells <clueLoc>of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<event uncertainty="doubtful" id="E109">
<type class="Transcription" />
<theme idref1="F5" idref="F4" />
<clue>Peripheral blood mononuclear cells (pbmc) and <clueLoc>bone marrow cells of 26 patients</clueLoc> were examined for c-fos, c-myc, p53 and the hybrid bcr/abl mRNA <clueType>levels</clueType>.</clue>
</event>
<sentence id="S4">Results indicated that (i) constitutive <term sem="Other" id="T13" lex="c-fos_transcript_level"><term sem="RNA_molecule" id="T14" lex="c-fos_transcript">c-fos transcript</term> levels</term> are significantly higher in <term sem="Multicellular_organism_natural" id="T15" lex="patient">patients</term> subsequently responding to <term sem="Other" id="T16" lex="IFN-alpha_therapy"><term sem="Protein_molecule" id="T17" lex="IFN-alpha">IFN-alpha</term> therapy</term> (p &lt; 0.01) and positively correlated with the proportion of <term sem="Cell_natural" id="T18" lex="lymphocyte">lymphocytes</term> (r = 0.6895, p &lt; 0.01) and negatively with the proportion of <term sem="Cell_natural" id="T19" lex="immature_cell">immature cells</term> (r = -0.568, p &lt; 0.01) contained in the <term sem="Cell_natural" id="T20" lex="pbmc">pbmc</term> preparations tested, (ii) <term sem="Other" id="T21" lex="constitutive_mRNA_levels"><term sem="RNA_family_or_group" id="T22" lex="constitutive_mRNA">constitutive mRNA</term> levels</term> <term sem="RNA_molecule" id="A10">of</term> the <term sem="RNA_molecule" id="T23" lex="hybrid_bcr/abl">hybrid bcr/abl</term>, <term sem="RNA_molecule" id="T24" lex="c-myc">c-myc</term> and <term sem="RNA_molecule" id="T25" lex="p53">p53</term> are positively correlated with each other, but failed to relate to <term sem="Other" id="A8">disease parameters</term>, and (iii) acute and chronic in vivo exposure to <term sem="Protein_molecule" id="T26" lex="IFN-alpha">IFN-alpha</term> is accompanied by upregulation of <term sem="RNA_molecule" id="T27" lex="c-fos">c-fos</term> and downregulation of <term sem="Other" id="T29" lex="c-myc_mRNA_level"><term sem="RNA_molecule" id="T30" lex="c-myc_mRNA">c-myc</term> <term sem="RNA_molecule" id="A9">mRNA</term> levels</term> in <term sem="Multicellular_organism_natural" id="T31" lex="responder_patient">responder <term sem="Multicellular_organism_natural" id="T32" lex="patient">patients</term></term>.</sentence>
<event id="E10">
<type class="Transcription" />
<theme idref="T14" />
<clue>Results indicated that (i) constitutive c-fos transcript <clueType>levels</clueType> are significantly higher <clueLoc>in patients</clueLoc> subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
<comment>NER T23,T24,T25,T27,T30 MOD</comment>
</event>
<event id="E11">
<type class="Positive_regulation" />
<theme idref="E10" />
<cause idref="T17" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly <clueType>higher</clueType> in patients subsequently <linkCause>responding to</linkCause> IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event id="E12">
<type class="Correlation" />
<theme idref="E10" />
<theme idref="T18" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and <clueType>positively correlated</clueType> <linkTheme>with</linkTheme> the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained <clueLoc>in the pbmc preparations tested</clueLoc>, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event id="E13">
<type class="Correlation" />
<theme idref="E10" />
<theme idref="T19" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively <clueType>correlated</clueType> with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and <clueType>negatively</clueType> <linkTheme>with</linkTheme> the proportion of immature cells (r = -0.568, p &lt; 0.01) contained <clueLoc>in the pbmc preparations tested</clueLoc>, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event id="E14">
<type class="Correlation" />
<theme idref1="A10" idref2="T23" idref="T22" />
<theme idref1="A10" idref2="T24" idref="T22" />
<theme idref1="A10" idref2="T25" idref="T22" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are <clueType>positively correlated</clueType> <linkTheme>with</linkTheme> <corefTheme>each other</corefTheme>, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event assertion="non-exist" id="E15">
<type class="Correlation" />
<theme idref1="A10" idref2="T23" idref="T22" />
<theme idref="A8" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but <clueType>failed to relate</clueType> <linkTheme>to</linkTheme> disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is accompanied by upregulation of c-fos and downregulation of c-myc mRNA levels in responder patients.</clue>
</event>
<event id="E16">
<type class="Positive_regulation" />
<theme idref1="A9" idref="T27" />
<cause idref="T26" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is <clueType>accompanied by upregulation</clueType> <linkTheme>of</linkTheme> c-fos and downregulation of c-myc mRNA levels <clueLoc>in responder patients</clueLoc>.</clue>
</event>
<event id="E17">
<type class="Negative_regulation" />
<theme idref1="A9" idref="T30" />
<cause idref="T26" />
<clue>Results indicated that (i) constitutive c-fos transcript levels are significantly higher in patients subsequently responding to IFN-alpha therapy (p &lt; 0.01) and positively correlated with the proportion of lymphocytes (r = 0.6895, p &lt; 0.01) and negatively with the proportion of immature cells (r = -0.568, p &lt; 0.01) contained in the pbmc preparations tested, (ii) constitutive mRNA levels of the hybrid bcr/abl, c-myc and p53 are positively correlated with each other, but failed to relate to disease parameters, and (iii) acute and chronic in vivo exposure to IFN-alpha is <clueType>accompanied by</clueType> upregulation of c-fos and <clueType>downregulation</clueType> <linkTheme>of</linkTheme> c-myc mRNA levels <clueLoc>in responder patients</clueLoc>.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
